Biogen has been navigating a slow pick-up in sales for its Alzheimer's drug Leqembi in the United States after concerns over cost, efficacy and side effects. Sage, whose shares fell 74.9 per cent last year, abandoned the development of its drug dalzanemdor after multiple trial failures.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3iULQau
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment